Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo

[1]  R. Murali,et al.  Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. , 1999, Experimental and molecular pathology.

[2]  D. O’Rourke,et al.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[4]  V. Dive,et al.  Phosphinic peptides, the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors. , 1998, The Biochemical journal.

[5]  D. O’Rourke,et al.  Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. , 1997, DNA and cell biology.

[6]  R. Murali,et al.  Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor , 1997, Nature Biotechnology.

[7]  Bert Vogelstein,et al.  Cell-cycle arrest versus cell death in cancer therapy , 1997, Nature Medicine.

[8]  R. Murali,et al.  Therapeutic peptides and peptidomimetics. , 1997, Current opinion in biotechnology.

[9]  S. Langston.  Peptidomimetics and small molecule design , 1997 .

[10]  David Cowburn,et al.  Solution Structures of FcεRI α-Chain Mimics: A β-Hairpin Peptide and Its Retroenantiomer , 1997 .

[11]  D. Weiner,et al.  Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes , 1997, Nature Biotechnology.

[12]  Andrew J. Martin,et al.  Antibody-antigen interactions: contact analysis and binding site topography. , 1996, Journal of molecular biology.

[13]  H. Wajant,et al.  Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[14]  R. Juliano,et al.  Macromolecular versus smallmolecule therapeutics: drug discovery, development and clinical considerations , 1996 .

[15]  C. Auffray,et al.  Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation , 1996, Nature Biotechnology.

[16]  Makoto Katsumata,et al.  Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.

[17]  J. Kelly,et al.  Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics. , 1994, Bioorganic & medicinal chemistry.

[18]  W. Dougall,et al.  Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. , 1994, Oncogene.

[19]  G. Moore.  Designing peptide mimetics. , 1994, Trends in pharmacological sciences.

[20]  P. Carter,et al.  X‐ray structures of fragments from binding and nonbinding versions of a humanized anti‐CD18 antibody: Structural indications of the key role of VH residues 59 to 65 , 1994, Proteins.

[21]  V. Hruby,et al.  Conformational and topographical considerations in the design of biologically active peptides , 1993, Biopolymers.

[22]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[23]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Mayer,et al.  Structure‐activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction , 1991, British journal of pharmacology.

[25]  M Kahn,et al.  Design and synthesis of a mimetic from an antibody complementarity-determining region. , 1991, Science.

[26]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[27]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[28]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[29]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[30]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[31]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[32]  R. Weinberg,et al.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Mullins,et al.  Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[35]  R. Weinberg,et al.  Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene , 1984, Nature.

[36]  R. Murali,et al.  Structure-based design of immunologically active therapeutic peptides , 1998, Immunologic research.

[37]  M. Akamatsu,et al.  Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. , 1997, Bioorganic & medicinal chemistry.

[38]  R. Juliano,et al.  Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. , 1996, Trends in biotechnology.

[39]  Harry C. J. Ottenheijm,et al.  CASE HISTORIES OF PEPTIDOMIMETICS : PROGRESSION FROM PEPTIDES TO DRUGS , 1994 .

[40]  D. Weiner,et al.  Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. , 1989, Oncogene.

[41]  R. Poljak,et al.  The structural basis of antigen-antibody recognition. , 1987, Annual review of biophysics and biophysical chemistry.

[42]  R. Weinberg,et al.  Development of monoclonal antibodies reactive with the product of the neu oncogene. , 1986, Symposium on Fundamental Cancer Research.